Skip navigation

Lonza Group AG

Pharmaceuticals
Switzerland
2016 Revenue (US$ Millions)$4,059
Revenue Growth (%)8.65%
Net Income (US$ Millions)$296
Earnings Per Share (US$)$5.59
EPS Growth Rate (%)8.17%
Profit Margin7.28%
Total Equity (US$ Millions)$2,314
Return on Equity (%)14.10%
Long Term Debt (US$ Millions)$1,543
Debt To Equity Ratio (%)0.67%
Total Assets (US$ Millions)$6,708
Current Assets (US$ Millions)$2,029
Current Liabilities (US$ Millions)$1,603
Cost of Goods Sold (US$ Millions)$2,683
Inventory Turnover3.05